Immunostimulation in Cancer Patients

  • Yuichi Yamamura
  • Ichiro Azuma
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)

Abstract

The studies on the cancer immunology and its application to the cancer immunotherapy in humans are attractive subjects for the immunologists and oncologists. However, in order to discuss the immunostimulation and its application to cancer patients, the following should be considered.

Keywords

Survival Period Cancer Immunotherapy Mycolic Acid Adjuvant Activity Muramyl Dipeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Azuma, I., T. Taniyama, F. Hirao and Y. Yamamura. 1974. Antitumor activity of cell wall skeletons and peptidoglycolipids of mycobacteria and related microorganisms in mice and rabbits. Gann 65: 493.PubMedGoogle Scholar
  2. 2.
    Azuma, I., and Y. Yamamura. 1979. Immunotherapy of cancer with BCG cell-wall skeleton and related materials. Gann Monogr. Cancer Res. 24: 121.Google Scholar
  3. 3.
    Cheever, M. A., P. D. Greenberg and A. Fefer. 1981. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2. J. Immunol. 126: 1318.PubMedGoogle Scholar
  4. 4.
    Cheever, M. A., P. D. Greenberg, A. Fefer and S. Gillis. 1982. Augmentation of the anti-tumor therapeutic efficacy of longterm cultured T lymphocytes by in vivo administration of purified interleukin. J. Exp. Med. 155: 968.PubMedCrossRefGoogle Scholar
  5. 5.
    Ellouz, F., A. Adam, R. Ciorbaru and E. Lederer. 1974. Minimal structure requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59: 1317.PubMedCrossRefGoogle Scholar
  6. 6.
    Gutterman, J. U., S. Fein, J. Quesada, S. J. Horning, J. L. Levine, R. Alexanian, L. Bernhardt, M. Kramer, H. Speigel, W. Colburn, P. Trown, T. Merigan and Z. Dziewanowska. 1982. Recombinant leukocyte A interferon: Pharmacokinetics, single dose tolerance and biologic effects in cancer patients. Annals of Int. Med. (in press).Google Scholar
  7. 7.
    Fidler, I. J., S. Sone, W. E. Fogler and J. L. Barnes. 1981. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. USA 78: 1680.PubMedCrossRefGoogle Scholar
  8. 8.
    Fidler, I. J., S. Sone, W. E. Fogler, D, Smith, D. G. Braun, L. Tarcsay, R. J. Gisler and A. J. Schroit. 1982. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J. Biol. Response Modifiers (in press).Google Scholar
  9. 9.
    Hatzubai, A., D. G. Malone, R. Levy. 1981. The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J. Icmuunol. 126: 2397.Google Scholar
  10. 10.
    Irie, R. F., P. C. Jones, D. L. Morton and N. Sidell. 1981. In vitro production of human antibody to a tumour-associated foetal antigen. Br. J. Cancer 44: 262.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones, P. C., L. L. Sze, P. Y. Liu, D. L. Morton and R. F. Irie. 1981. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl. Cancer Inst. 66: 249.PubMedGoogle Scholar
  12. 12.
    Kaieda, T., M. Okada, N. Yoshimura, S. Kishimoto, Y. Yamamura and I. Azuma. 1982. A human helper T cell clone secreting both killer helper factor(s) and T cell-replacing factor(s). J. Immunol. 129: 46.PubMedGoogle Scholar
  13. 13.
    Kotani, S., Y. Watanabe, F. Kinoshita, T. Shimono, I. Morisaki, T. Shiba, S. Kusumoto, Y. Tarumi and K. Ikenaka. 1975. Immunoadjuvant activities of synthetic N-acetylmuramylpeptides or amino acids. Biken J. 18: 105.PubMedGoogle Scholar
  14. 14.
    Lederer, E. 1982. Immunomodulation by muramyl peptides: Recent developments. Clin. Immunol. Newsletter 3: 83.CrossRefGoogle Scholar
  15. 15.
    Lotze, M.T., E. A. Grimm, A. Mazumder, J. L. Strausser and S. A. Rosenberg. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 41: 4420.PubMedGoogle Scholar
  16. 16.
    Lotze, M. T., B. R. Line, D. J. Mathisen and S. A. Rosenberg. 1980. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGFP: Implications for the adoptive immunotherapy of tumors. J. Immunol. 125: 1487.PubMedGoogle Scholar
  17. 17.
    Magnani, J. L., M. Brockhaus, D. F. Smith, V. Ginsburg, M. Blaszcayk, K. F. Mitchell, Z. Steplewski and H. Koprowski. 1981. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 212: 55.PubMedCrossRefGoogle Scholar
  18. 18.
    Marx, J. L. 1982. Monoclonal antibodies in cancer. Science 216: 283.PubMedCrossRefGoogle Scholar
  19. 19.
    McKneally, M. F., C. Mayer, L. Lininger, H. W. Kausel, J. B. Mcllduff, T. M. Older, E. D. Foster and R. D. Alley. 1981. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J. Thorac. Cardiovas. Surg. 81: 485.Google Scholar
  20. 20.
    Miller, R. A. and R. Levy. 1981. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2: 226.PubMedCrossRefGoogle Scholar
  21. 21.
    Miller, R. A., D. G. Maloney, J. McKillop, and R. Levy. 1981. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 78.PubMedGoogle Scholar
  22. 22.
    Miller, R. A., D. G. Maloney, R. Warnke, and R. Levy. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Eng. J. Med. 306: 517.CrossRefGoogle Scholar
  23. 23.
    Moller, G. (ed.). 1982. Antibody Carriers of Drugs and Toxins in Tumor Therapy. Immunol. Rev., Vol. 62.Google Scholar
  24. 24.
    Mountain, C. F. and M. H. Gail. 1981. Surgical adjuvant intra-pleural BCG treatment for Stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 82: 649.Google Scholar
  25. 25.
    Ogura, T., M. Namba, Y. Yamamura and I. Azuma. 1979. Immunotherapeutic effect of BCG and Nocardia rubra cell-wall skeletons on syngeneic tumors in rats. In W. D. Terry and Y. Yamamura (eds.) Immunobiology and Immunotherapy of Cancer. Elsevier North/Holland Publishers, New York.Google Scholar
  26. 26.
    Okada, M., N. Yashimura, T. Kaieda, Y. Yamamura and T. Kishimoto. 1981. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc. Natl. Acad. Sci. USA 78: 7717.PubMedCrossRefGoogle Scholar
  27. 27.
    Pukel, C. S., K. O. Lloyd, L. R. Travasos, W. G. Dippold, H. F. Oettgen and L. J. Old. 1982. GD3 a prominent ganglioside of human melanoma. J. Exp. Med. 155: 1133.PubMedCrossRefGoogle Scholar
  28. 28.
    Ritz, J., J. M. Pesando, J. Notis-McConarty, H. Lazarus and S. Schlossman. 1980. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature 283: 583.PubMedCrossRefGoogle Scholar
  29. 29.
    Ritz, J., J. M. Pesando, S. E. Sallan, L. A. Clavell, J. Notis-McConarty, P. Rosenthal and S. F. Schlossman. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141.PubMedGoogle Scholar
  30. 30.
    Saiki, I., Y. Tanio, M. Yamawaki, M. Uemiya, S. Kobayashi, T. Fukuda, H. Yukimasa, Y. Yamamura and I. Azuma. 1981. Adjuvant activity of quinonyl-N-acetylmuramyldipeptides in mice and guinea pigs. Infect. Immun. 31: 114.PubMedGoogle Scholar
  31. 31.
    Sato, H., T. Ochiai, H. Sato, R. Hayashi, K. Watanabe, T. Asano, K. Isono and T. Tanaka. 1982. Result of randomized clinical trial of immunotherapy with Nocardia rubra-CWS. J. Jap. Surg. Soc. (in Japanese) (in press).Google Scholar
  32. 32.
    Terry, W. D. and S. T. Rosenberg (ed). 1982. Immunotherapy of Human Cancer. Excepta Medica, Amsterdam.Google Scholar
  33. 33.
    Umezawa, H., T. Aoyagi, H. Suda, M. Hamada and T. Takeuchi. 1976. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot. 29: 97.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamamura, Y., I. Azuma, K. Sugimura, M. Yamawaki, M. Uemiya, S. Kusumoto, S. Okada and T. Shiba. 1976. Adjuvant activity of 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine. Gann 67: 867.PubMedGoogle Scholar
  35. 35.
    Yamamura, Y., M. Sakatani, T. Ogura and I. Azuma. 1979. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer 43: 1314.PubMedCrossRefGoogle Scholar
  36. 36.
    Yamamura, Y., T. Ogura, M. Sakatani, F. Hirao, S. Kishimoto, K. Furuse, M. Kawahara, M. Fukuoka, M. Takada, O. Kuwahara and N. Ogawa. 1982a. Randomized controlled study on adjuvant immunotherapy for unresectable lung cancer with Nocardia rubra cell wall skeleton. Gan to Kagakuryoho (in Japanese) (in press).Google Scholar
  37. 37.
    Yamamura, Y., T. Ogura, M. Sakitani, F. Hirao, S. Kishimoto, K. Furuse, M. Kawahara, M. Fukuoka, M. Takada, O. Kuwahara, H. Ikegami, S. Nakamura and N. Ogawa. 1982b. Clinical effect of Nocardia rubra cell wall skeleton (N-CWS) on lung cancer with malignant pleural effusion. Gan to Kagakuryoho (in Japanese) (in press).Google Scholar
  38. 38.
    Yamamura, Y., K. Yasumoto, T. Ogura and I. Azuma. 1981. Nocardia rubra cell wall skeleton in the therapy of animal and human cancer. In E. M. Hersh (ed.), Augmenting Agents in Cancer Immunology. Raven Press, New York.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Yuichi Yamamura
    • 1
  • Ichiro Azuma
    • 2
  1. 1.Osaka UniversityYamada-oka, Suita, Osaka 565Japan
  2. 2.Section of ChemistryInstitute of Immunological Science Hokkaido UniversityKita-ku, Sapporo 060Japan

Personalised recommendations